A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet
A Phase IV Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 1.0 mg/kg Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis Involving the Hands and/or Feet
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provide written informed consent and Health Insurance Portability and Accountability Act of 1996 (HIPAA) documents
- Be aged 18 years or older
- Have chronic (6 months or greater) moderate to severe plaque psoriasis involving the hands and/or feet with or without pustules and with or without psoriasis at other sites
- Have a PGA rating of moderate (3) or severe (4) for hand and/or foot psoriasis
- Be a candidate for systemic therapy in the opinion of the investigator
- Be naive to efalizumab treatment
- Weigh no more than 125 kg
- For women of childbearing potential, use a method of contraception acceptable to the investigator to prevent pregnancy and agree to continue to practice an acceptable method of contraception for the duration of their participation in the study and for 6 weeks after the last dose of efalizumab
Exclusion Criteria:
- Have a history of hypersensitivity to efalizumab or any of its components
- Are using any excluded therapy
- Have a history of or ongoing alcohol or illegal drug abuse
- Have a history of or an ongoing uncontrolled serious bacterial, viral, fungal, or atypical mycobacterial infection. This includes diagnoses that required more than 2 weeks of therapy, such as endocarditis and osteomyelitis, that have been treated in the past 6 months. In addition, if the patient is currently receiving antibiotics, antivirals, or antifungals for an infection or for suppression or prophylaxis for any diagnosis, the patient will be excluded.
- Have any history of opportunistic infections (e.g., systemic fungal infections, parasites)
- Are seropositive for hepatitis B antigen, hepatitis C antibody, or human immunodeficiency virus (HIV). Patients will undergo testing during screening, and any patients who are seropositive for hepatitis B antigen, hepatitis C antibody, or HIV will be excluded.
- Have a history of active tuberculosis or are currently undergoing treatment for tuberculosis. A purified protein derivative (PPD) test or chest x-ray will be performed at the screening visit. Patients with a positive PPD test (not due to BCG vaccination) or chest x-ray will be excluded.
- Have the presence or history of malignancy within the past 5 years, including lymphoproliferative disorders. Patients with a history of fully resolved basal or squamous cell skin cancer may be enrolled.
- Are pregnant or lactating women
- Have a diagnosis of hepatic cirrhosis, regardless of cause or severity
- Have a history of thrombocytopenia
- Have a history of hemolytic anemia
- Have a history of clinically significant anemia
- Have a WBC count <4,000 cells/uL or >14,000 cells/uL
- Have a hematocrit (HCT) <30% or a hemoglobin (Hgb) level <11 g/dL
- Have a platelet count <150,000 cells/uL
- Have hepatic enzyme levels ≥3 times the upper limit of normal
- Have a serum creatinine level ≥2 times the upper limit of normal
- Have been exposed to any experimental drugs or treatments within 30 days or 5 half-lives, whichever is longer, prior to the screening visit
- Have had any previous exposure to efalizumab
- Have been vaccinated with a live virus or live bacteria within the 14 days prior to the first dose of efalizumab
- Have any medical condition that, in the judgment of the investigator, would jeopardize the patient's safety following exposure to study drug (efalizumab or placebo equivalent) or would significantly interfere with the patient's ability to comply with the provisions of this protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
The primary efficacy outcome measure is the proportion of patients who achieve a PGA rating of clear (0), almost clear (1), or mild (2) at Day 84.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
The proportion of patients who achieve a PGA rating of clear (0), almost clear (1), or mild (2) at Day 42
|
|
The proportion of patients who achieve a PGA rating of clear (0) or almost clear (1) at Day 84
|
|
The change from Day 0 to Day 84 in the following PRO measures: SF 36, PDS, Work Loss Questionnaire
|
|
The change from Day 0 in PGA rating (i.e., the number of categories changed) at Day 84
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ACD3753g
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.